{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 17 of 169', '2 Trial identification', 'EudraCT number: 2016-004200-65', 'IND number: 123797', 'ClinicalTrials.gov number: NCT03131648', '3 Schematic of trial design', 'Panel 1 Trial design', 'LP0162-1325', 'Tralokinumab 300mg', 'Placebo', 'Home use option', 'Screening and Follow-up Visits', 'Blood sample only visit', 'Treatment Period', 'Screening', 'Intial treatment', 'Maintenance treatment', 'Safety follow-up', 'Subjects with clinical response IGA=0,1 or EASI75', 'Off-treatment period', '3:1 rando', '2:2:1 rando', 'Tralokinumab', '585 patients', '300mg', 'every 2nd week after', '600mg loading', 'Placebo', '195 patients', 'every 2nd week after', '600mg loading', 'Open label treatment', 'Open label tralokinumab 300mg', 'Subjects not achieving IGA=0, 1 or EASI75 at 16w or were transferred later', 'Optional TCS and optional home use', 'Selected countries only', 'Visit No. 1', '3', '12', '20', '30', '31', '-6w', '0', '16w', '32w', '52w', '66w 68w', 'Weeks from start of treatment', \"EASI 75, at least 75% reduction in EASI score; IGA, Investigator's Global Assessment; No, number; rando,\", 'randomisation; TCS, topical corticosteroid; W, week.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 18 of 169', '4 Schedule of procedures (SoP)', 'Panel 2 Schedule of trial procedures: screening and initial treatment period', 'Screening\u00b9', 'Initial treatment period', 'Visit', '1\u00b9', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11\u00b2', '12\u00b3', 'Week', '-6', '-2', '0', '2', '4', '6', '8', '10', '12', '14', '15', '16', 'Day', '-42', '-14', '0', '14', '28', '42', '56', '70', '84', '98', '105', '112', 'Visit window (days)', '+3', '-3', 'NA', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '3', 'Trial population and eligibility (Section 8 and Appendix 4B)', 'Informed consents', 'X4', 'X5', 'Eligibility', 'X', 'X', 'Trial products and randomisation (Section 9)', 'Initiation of emollients (bcg. treatment)6', 'X', 'Concomitant medication/procedures', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Randomisation', 'X', \"X'\", 'IMP administration and compliance', 'X8', 'X8', 'X8', 'X', 'X', 'X', 'X', 'X', 'X7,8', 'Investigator assessments at screening/baseline (Section 10.2)', 'C-SSRS', 'X', 'Demographics (age) and BSA', 'X', 'Other demographics and medical history', 'X', 'Height and weight', 'X', 'Investigator assessments of efficacy (Section 10.3.1)', 'IGA', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 19 of 169', 'Panel 2 Schedule of trial procedures: screening and initial treatment period (continued)', 'Screening', 'Initial treatment period', 'Visit', '1\u00b9', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11\u00b2', '12\u00b3', 'Week', '-6', '-2', '0', '2', '4', '6', '8', '10', '12', '14', '15', '16', 'Investigator assessments of efficacy (Section 10.3.1)', 'EASI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'SCORAD', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Subject assessments of efficacy (Section 10.3.2)', 'eDiary training', 'X', 'eDiary completion9', 'POEM and DLQI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'EQ-5D-5L and HADS', 'X', 'X', 'X', 'X', 'X', 'SF-36 and WPAI-GH', 'X', 'X', 'TSQM', 'X', 'X', 'Safety assessments (Sections 10.4 and 11)', 'Vital signs', 'X', 'X8', 'X8', 'X8', 'X', 'X', 'X', 'X', 'X', 'X8', 'Physical examination', 'X', 'X', 'X', 'ECG', 'X', 'X', 'X', 'X', 'Serum pregnancy test', 'X', 'Urine pregnancy test', 'X', 'X', 'X', 'X', 'X', 'Hepatitis B, C and HIV', 'X', 'Serum chemistry, haematology, and IgE', 'X10', 'X', 'X', 'X', 'X', 'X', 'Urinalysis', 'X', 'X', 'X', 'X', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}